Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $65.62 -0.35%
EPS Growth %: +22.5%
Financial Fact:
Diluted net income (loss) per share: 0.02
Today's EPS Names:
FCNCA, PBCO, ARBV, More
EPS Growth %: +22.5%
Financial Fact:
Diluted net income (loss) per share: 0.02
Today's EPS Names:
FCNCA, PBCO, ARBV, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q3 EPS of $0.56, $0.05 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $187.06 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Sees Q4 2011 EPS of $0.63-$0.69, versus the consensus of $0.70. Sees Q4 2011 revenue of $187-$200 million, versus the consensus of $199 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Airlines (AAL) Tops Q2 EPS by 12c, Offers Guidance
- Supermicro Q4 revenue near low end; gross margins beat guidance
- Origin Bancorp, Inc. (OBK) Tops Q2 EPS by 9c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
